Morepen Laboratories Gestione
Gestione criteri di controllo 3/4
Morepen Laboratories Il CEO è Sushil Suri, nominato in Oct2000, ha un mandato di 24.08 anni. possiede direttamente 1.22% delle azioni della società, per un valore di ₹ 496.16M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.9 anni e 4.8 anni.
Informazioni chiave
Sushil Suri
Amministratore delegato
₹39.1m
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 24.1yrs |
| Proprietà del CEO | 1.2% |
| Durata media del management | 7.9yrs |
| Durata media del Consiglio di amministrazione | 4.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump
Aug 20
Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)
Aug 09Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified
Jul 05Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?
Jun 13Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing
Apr 23Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 22Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 21Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Apr 05Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?
Sep 14Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?
Mar 12Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay
Feb 22Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 07Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain
Jan 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03
Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?
Dec 16Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Nov 28Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹1b |
| Jun 30 2024 | n/a | n/a | ₹1b |
| Mar 31 2024 | ₹39m | n/a | ₹962m |
| Dec 31 2023 | n/a | n/a | ₹761m |
| Sep 30 2023 | n/a | n/a | ₹531m |
| Jun 30 2023 | n/a | n/a | ₹477m |
| Mar 31 2023 | ₹48m | ₹44m | ₹387m |
| Dec 31 2022 | n/a | n/a | ₹428m |
| Sep 30 2022 | n/a | n/a | ₹553m |
| Jun 30 2022 | n/a | n/a | ₹768m |
| Mar 31 2022 | ₹91m | ₹87m | ₹1b |
| Dec 31 2021 | n/a | n/a | ₹1b |
| Sep 30 2021 | n/a | n/a | ₹1b |
| Jun 30 2021 | n/a | n/a | ₹1b |
| Mar 31 2021 | ₹54m | ₹51m | ₹971m |
| Dec 31 2020 | n/a | n/a | ₹814m |
| Sep 30 2020 | n/a | n/a | ₹684m |
| Jun 30 2020 | n/a | n/a | ₹453m |
| Mar 31 2020 | ₹17m | ₹16m | ₹336m |
| Dec 31 2019 | n/a | n/a | ₹331m |
| Sep 30 2019 | n/a | n/a | ₹312m |
| Jun 30 2019 | n/a | n/a | ₹340m |
| Mar 31 2019 | ₹12m | ₹11m | ₹288m |
| Dec 31 2018 | n/a | n/a | ₹252m |
| Sep 30 2018 | n/a | n/a | ₹267m |
| Jun 30 2018 | n/a | n/a | ₹308m |
| Mar 31 2018 | ₹6m | ₹4m | ₹296m |
Compensazione vs Mercato: La retribuzione totale di Sushil ($USD 464.10K ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 271.25K ).
Compensazione vs guadagni: La retribuzione di Sushil è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Sushil Suri (60 yo)
24.1yrs
Mandato
₹39,112,000
Compensazione
Mr. Sushil Suri, B.Sc., FCA has been Managing Director of Morepen Laboratories Limited since October 2000. He has been Chairman of Morepen Laboratories Limited since October 2000 and has been its Director...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & MD | 24.1yrs | ₹39.11m | 1.22% ₹ 496.2m | |
| Whole-Time Director | 9.8yrs | ₹21.80m | 1.01% ₹ 408.4m | |
| Chief Financial Officer | 10.3yrs | ₹9.80m | Nessun dato | |
| General Manager of Process Engineering & Technology Transfer | no data | Nessun dato | Nessun dato | |
| Manager of Administration | no data | Nessun dato | 0.58% ₹ 236.3m | |
| Company Secretary & Compliance Officer | 6yrs | ₹1.84m | Nessun dato | |
| Functional Head of Talent Acquisition & HRBP | less than a year | Nessun dato | Nessun dato | |
| Chief Operating Officer of API | less than a year | Nessun dato | Nessun dato | |
| Head of Medipath Division | no data | Nessun dato | 0.42% ₹ 168.9m | |
| Head of International Business Development | no data | Nessun dato | Nessun dato | |
| Chief Executive Officer of Consumer Division | no data | Nessun dato | 0.56% ₹ 225.9m | |
| Chief of R&D | no data | Nessun dato | Nessun dato |
7.9yrs
Durata media
47.5yo
Età media
Gestione esperta: Il team dirigenziale di MOREPENLAB è esperto e expertise (durata media dell'incarico 7.9 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman & MD | 32.8yrs | ₹39.11m | 1.22% ₹ 496.2m | |
| Whole-Time Director | 5.3yrs | ₹21.80m | 1.01% ₹ 408.4m | |
| Independent Director | less than a year | Nessun dato | Nessun dato | |
| Independent Director | 5.3yrs | ₹520.00k | Nessun dato | |
| Independent Director | 4.4yrs | ₹300.00k | Nessun dato | |
| Independent Director | less than a year | Nessun dato | Nessun dato |
4.8yrs
Durata media
56yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MOREPENLAB sono considerati esperti (durata media dell'incarico 4.8 anni).